| 1 |
Home |
text |
| 2 |
News |
text |
| 3 |
Archive |
text |
| 4 |
Events |
text |
| 5 |
Partners |
text |
| 6 |
Media |
text |
| 7 |
Videos |
text |
| 8 |
SUBSCRIBE |
text |
| 9 |
- |
image |
| 10 |
latest issue |
text |
| 11 |
Using Zebrafish to Advance Disease Research |
text |
| 12 |
Pioneering precision medicine in rheumatoid arthritis |
text |
| 13 |
Companion Diagnostics, Precision Medicine and Immuno-Oncology Therapies |
text |
| 14 |
Leveraging Real-World Data for COVID-19 Research: Challenges and Opportunities |
text |
| 15 |
COVID‑19 and pharmacogenomics: an a***ociation that warrants comprehensive a***essment |
text |
| 16 |
Lessons from oncology drive precision medicine across clinical specialties |
text |
| 17 |
A New Playbook for Cure-Seeking Nonprofits |
text |
| 18 |
Personalization and standardization: Can we have it all? |
text |
| 19 |
Personalized Medicine in the Aftermath of COVID-19 |
text |
| 20 |
Focused On Precision Data |
text |
| 21 |
Diagnosing and Tracking COVID-19 Infections Leveraging Next-Gen Sequencing |
text |
| 22 |
Quick Take on Pharmacogenomics |
text |
| 23 |
The Burden of Proof – What Laboratories Need to Know About Evidence Development Before Launching a New Test |
text |
| 24 |
Expanding areas of impact for clinical diagnostics and precision medicine |
text |
| 25 |
How Cancer Patients Should Respond to the COVID-19 Pandemic |
text |
| 26 |
Quick Takes |
text |
| 27 |
The Journey to a COVID-19 Diagnostic Test |
text |
| 28 |
Clinical and real-world insights |
text |
| 29 |
The Licensing Conundrum |
text |
| 30 |
Why Standardizing the Use of Precision Medicine Should Be a Top Priority for Cancer Centers |
text |
| 31 |
Expert Feedback on Pain Points and Evolution in The Precision Medicine Landscape |
text |
| 32 |
- |
image |
| 33 |
Genetic testing for heart diseases may help patients and families identify risks |
text |
| 34 |
Read More |
text |
| 35 |
- |
image |
| 36 |
Konica Minolta Precision Medicine (KMPM) Launches Care for COVID Program |
text |
| 37 |
Read More |
text |
| 38 |
- |
image |
| 39 |
Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints |
text |
| 40 |
Read More |
text |
| 41 |
- |
image |
| 42 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel) |
text |
| 43 |
Read More |
text |
| 44 |
- |
image |
| 45 |
Thermo Fisher Scientific’s Response to COVID-19 Continues to Expand to Support Development and Production of Ther***utics and Vaccines |
text |
| 46 |
Read More |
text |
| 47 |
- |
image |
| 48 |
Multiple Myeloma Research Foundation (MMRF) Launches CureCloud to Democratize Healthcare for Cancer Patients |
text |
| 49 |
Read More |
text |
| 50 |
- |
image |